Find Funding Opportunities

This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH. This Parent Funding Opportunity Announcement does not accept clinical trials.

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.

This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the scholar can be considered to remain as an investigator within the intramural program.

(RFA-NS-19-025 is being reissued to accommodate an additional receipt date). The purpose of this funding opportunity announcement (FOA) is to invite applications for the Specialized Clinical Centers (hubs) of the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net will serve as the cornerstone of the NIHs Helping to End Addiction Long-term (HEAL) Initiative. EPPIC-Net will provide a robust and readily accessible infrastructure for carrying out in depth phenotyping and biomarker studies in patients with specific pain conditions, and the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain from partners in academia or industry. Studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs. EPPIC-Net will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and approximately 10 specialized clinical centers (hubs). The purpose of this funding opportunity announcement (FOA) is to invite applications for the hubs within EPPIC-Net. A hub will typically be a regional medical center that will actively enroll subjects into clinical trials and studies performed in EPPIC-Net. Each hub should have ready access to patient populations with specific pain conditions and have expertise in characterization of that pain condition. A hub will additionally provide scientific leadership and administrative oversight to its multiple (2-10) satellite sites (spokes). This FOA solicits applications EPPIC-Net Specialized Clinical Centers. Separate FOAs have been issued to solicit applications for the Clinical Coordinating Center (RFA-NS-18-036) and Data Coordinating Center (RFA-NS-18-035). Clinical trials conducted through EPPIC-Net may come from a variety of sources including the HEAL Partnership, as described above, or from separate NIH funding announcements.

Notice Special Interest Administrative Supplements Research Sexual Gender Minority SGM) Populations Admin Supp Clinical Trial Optional) Notice Number: NOT-OD-19-102 Key Dates Release Date: April 17, 2019 First Available Due Date: 18, 2019 Expiration Date: 19, 2019 Related Announcements PA 18-591 Issued Sexual Gender Minority Research Office SGMRO) National Cancer Institute NCI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Center Complementary Integrative Health NCCIH) applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Office Behavioral Social Sciences Research OBSSR) Office Research Women's Health ORWH) Purpose Purpose mission the NIH to seek fundamental knowledge the nature behavior living systems, the application that knowledge enhance health, lengthen life, reduce illness disability. NIH committed supporting research will increase scientific understanding the health wellbeing various population subpopulation groups study effectiveness evidence-based health interventions services individuals within those groups. NIH places high priority research populations appear have distinctive health risk profiles have received insufficient attention investigators. Supplement provides administrative support expand existing research focus sexual gender minority SGM) populations, include are limited to) lesbian, gay, bisexual, transgender people, individuals difference disorders sex development, sometimes referred as intersex. Basic, social, behavioral, clinical, translational, health services research relevant the missions the sponsoring Institutes, Centers Offices be proposed. Potential applicants also encouraged review recent portfolio analyses NIH-funded SGM research found at https://dpcpsi.nih.gov/sgmro/reports) identify gaps research may relevant this Notice Special Interest. . Background Institute Medicine IOM), the National Academy Medicine) report issued March 2011 http://www.nationalacademies.org/hmd/Reports/2011/The-Health-of-Lesbian…) stated, reference SGM health, the existing body evidence sparse, that substantial research needed." situation improved, there still need further research a range health-related issues. NIH encourages potential applicants read IOM report, a number specific issues raised discussed therein; however, readers should note this IOM report addresses most, not all, the populations within NIH's SGM definition. Recent data national health surveys targeted studies suggest prevalence rates some health conditions significantly higher among SGM populations for general population. Sexual gender minority" an umbrella term encompasses lesbian, gay, two-spirit, bisexual, transgender populations well those whose sexual orientation, gender identity expressions, reproductive development varies traditional, societal, cultural, physiological norms. includes individuals disorders differences sex development DSD), sometimes known intersex. NIH uses term SGM these populations well for individuals within them. However, applicants study subpopulations, and/or adopt classification frameworks terminologies appropriate proposed research such understudied populations. Although has an increase SGM-focused health research recent years, remains need further research the health these populations. Specific Areas Research Interest Notice Special Interestcalls research will enrich scientific understanding how sexual orientation, gender identity, and/or being born DSD/Intersex conditions relate health health risks, perceptions expectations health, health behaviors, barriers access health-related services. Appropriate topics/studies these supplements include, are limited to, those listed below: Addition SGM individuals a study either originally excluded or not enrolled enough SGM participants make any meaningful comparisons between groups; studies need have sufficient power allow meaningful comparisons Expansion an ongoing SGM study focused one group add another; sample sizes need be powered allow meaningful comparisons Expansion questionnaires administered any setting where is relevant address issues sexual attraction, sexual behavior, sexual identity, gender identity, and/or gender expression Assessment reliability validity measures relevant sexual attraction, sexual behavior, sexual identity, gender identity, non-binary sex. Methodological innovations improve recruitment retention SGM individuals any research initiative Ethical, legal, social science research the implications genetic other research findings SGM populations. Scope Support Administrative supplements be used meet increased costs are within scope the approved award, that unforeseen the new renewal application grant progress report non-competing continuation support submitted. Applicants should propose research that, successful, contribute a greater understanding the health wellbeing sexual gender minority communities. Clinical Trials cannot proposed be added grants do include clinical trial since would constitute change scope. IC-Specific Considerations Applicants strongly encouraged discuss proposed supplement project the IC Program Official the approved award prior submission a supplement application order ensure the proposed activity fits the scientific priorities the IC is within scope the approved award. In addition contact the IC Program Official the approved award, applicants strongly encouraged include Scientific/Research Contact listed in Section VII. Agency Contacts in communications. Section VIII. Information award authorities regulations. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide and PA-18-591 must followed, the following additions: Application Due Date(s) – 18, 2019, 5:00 PM local time applicant organization. expiration date May 19, 2019. funding consideration, applicants must include NOT-OD-19-102” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Requests be one year support only. Research Strategy section the application limited 6 pages. process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify program contact the Institute supporting parent award a request been submitted response this FOA order facilitate efficient processing the request. budget cannot exceed 100,000 total costs. Inquiries Please direct inquiries the contact the Institute, Center Office supporting parent award: Della White, PhD National Center Complementary Integrative Health NCCIH) Telephone: 301-827-6358 whitede@mail.nih.gov Liz Perruccio, PhD National Cancer Institute NCI) Telephone: 240-276-6178 Email: liz.perruccio@nih.gov Tina Gatlin, PhD National Human Genome Research Institute NHGRI) Telephone: 301-402-2851 Email: gatlincl@mail.nih.gov Brad Newsome, PhD National Heart, Lung, Blood Institute NHLBI) Telephone: 301-827-8170 Email: brad.newsome@nih.gov Melissa Gerald, PhD National Institute Aging NIA) Telephone: 301-451-4503 Email: geraldmel@mail.nih.gov Robert Freeman, PhD National Institute Alcohol Abuse Alcoholism NIAAA) Telephone: 301-443-8820 Email: rfreeman@mail.nih.gov Phillip Renzullo, PhD National Institute Allergy Infectious Diseases NIAID) Telephone: 240-627-3041 Email: prenzullo@mail.nih.gov Heiyoung Park, Ph.D. National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-3507 Email: Heiyoung.Park@nih.gov Jeffrey Schulden, PhD National Institute Drug Abuse NIDA) Telephone: 301-402-1526 Email: schuldenj@nida.nih.gov Alberto Rivera-Rentas, PhD National Institute Deafness Other Communication Disorders NIDCD) Telephone: 301-402-6251 Email: riverara@nidcd.nih.gov Melissa Riddle, PhD National Institute Dental Craniofacial Research NIDCR) Telephone: 301-451-3888 Email: riddleme@nidcr.nih.gov Tamara Bavendam, M.D. National Institute Diabetes Digestive Kidney Diseases NIDDK) Telephone: 301-594-4733 Email: tamara.bavendam@nih.gov Thaddeus Schug, PhD National Institute Environmental Health Sciences NIEHS) Telephone: 984-287-3319 Email: schugt2@mail.nih.gov Tamara Lewis-Johnson, PhD National Institute Mental Health NIMH) Telephone: 301-594-7963 Email: tl247e@nih.gov Jennifer Alvidrez, PhD National Institute Minority Health Health Disparities NIMHD) Telephone: 301-594-9567 Email: jennifer.alvidrez@nih.gov Rebecca Henry, PhD, BSN, RN National Institute Nursing Research NINR) Telephone: 301-594-5976 Email: rebecca.henry@nih.gov Victoria Cargill, PhD Office Research Women’s Health ORWH) Telephone: 301-402-1770 Email: CargillV@od.nih.gov ICs without listed contact please reach to Program Officer listed the NoA the parent award.  

This Funding Opportunity Announcement (FOA) seeks grant applications to optimally and sustainably address late-stage implementation research questions to address scaling up evidence-based interventions at the population level for prevention and management of hypertension in low- and middle-income countries and small island developing states. For the purposes of this FOA, late-stage implementation research is defined as research to identify strategies to achieve sustainable uptake of proven-effective interventions in routine clinical and public health and community-based settings and maximize the positive impact on population health. Each awarded project is to conduct late-stage implementation research in one of six geographical regions (e.g., East Asia and the Pacific; Europe and Central Asia; Latin America and the Caribbean; Middle East and North Africa; South Asia; Sub-Saharan Africa). As a group, awardees will constitute a research alliance for hypertension implementation science research in low-resource settings with capabilities for addressing scale-up of evidence-based interventions at the population level for the prevention and management of hypertension. This program is not intended to support research that can be conducted primarily in and/or by the United States or other high-income institutions that do not meet eligibility criteria. This FOA uses the bi-phasic, milestone driven UG3/UH3 cooperative agreement mechanism. Awards made under this FOA will initially support a two-year milestone-driven needs assessment and planning, with possible transition to an implementation (UH3) phase of up to 4 additional years. Only UG3 projects that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases and are expected to include plans for project management and performance milestones for each phase.

The BRAIN Initiative and the neuroscience field as a whole is generating massive and diverse research data across different modalities, spatiotemporal scales and species in efforts to advance our understanding of the brain. The data types are being produced through development and application of innovative technologies in high-throughput -omics profiling, optical microscopy, electron microscopy, electrophysiological recording, macroscale neuroimaging, neuromodulation, and others. The BRAIN Initiative has made significant investments in the development of an infrastructure to make data available to the research community in a useful way. This infrastructure includes data archives, data standards, and software for data integration, analysis and machine learning. This Funding Opportunity Announcement (FOA) encourages secondary analysis of the large amounts of existing data related to the BRAIN Initiative. The data do not need to be held in one of the funded BRAIN Initiative data archives, but the data must be held in a data archive that is readily accessible to the research community. Support will be provided for innovative analysis of relevant existing datasets using conventional or novel analytic methods, data science techniques, and machine learning approaches. Support may also be requested to prepare and submit existing data into any of the BRAIN Initiative data archives. Investigators should not underestimate the time and effort that may be necessary to curate or harmonize data. Analyzed data, models and analytical tools generated under this FOA are expected to be deposited into an appropriate data archive. Since the BRAIN Initiative data archives are mostly making the data available to the research community through cloud-based storage, depositing the analyzed data, models and tools are expected to enhance opportunities to create a data sandbox where investigators can easily compare the results of their analysis with those from other research groups.